Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Dec;10(Suppl 1):i16-i24.
doi: 10.1093/ckj/sfx043. Epub 2017 Nov 28.

Intravenous iron therapy in patients with chronic kidney disease: recent evidence and future directions

Iain C Macdougall  1
Affiliations
Review

Intravenous iron therapy in patients with chronic kidney disease: recent evidence and future directions

Iain C Macdougall. Clin Kidney J. 2017 Dec.

Abstract

Current recommendations for the use of intravenous iron therapy in the management of anaemia in patients with chronic kidney disease (CKD) are based on limited clinical evidence. Since the publication of the Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Anaemia in Chronic Kidney Disease in 2012, a number of randomized clinical trials [notably, the Ferinject Assessment in Patients with Iron Deficiency Anaemia (FIND-CKD) and Randomized Trial to Evaluate IV and Oral Iron in Chronic Kidney Disease (REVOKE) trials] and observational studies have been completed, and a further large clinical trial-Proactive IV Iron Therapy in Dialysis Patients (PIVOTAL)-is currently underway. In this article, the implications of the findings from these recent studies are discussed and the critical evidence gaps that remain to be addressed are highlighted.

Keywords: CKD; ESRD; clinical trial; epidemiology; iron.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Proactive IV Iron Therapy in Dialysis Patients (PIVOTAL) Trial Design. ESA, erythropoiesis-stimulating agent; HD, haemodialysis; HF, heart failure; IV, intravenous; MI, myocardial infarction; R, randomisation; TSAT, transferrin saturation.
See this image and copyright information in PMC

References

    1. Wish JB. Assessing iron status: beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol 2006; 1 Suppl 1: S4–S8 - PubMed
    1. Fishbane S, Pollack S, Feldman HI. et al. Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988–2004. Clin J Am Soc Nephrol 2009; 4: 57–61 - PMC - PubMed
    1. Gotloib L, Silverberg D, Fudin R. et al. Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron. J Nephrol 2006; 19: 161–167 - PubMed
    1. Silverberg DS, Blum M, Agbaria Z. et al. The effect of IV iron alone or in combination with low-dose erythropoietin in the rapid correction of anaemia of chronic renal failure in the predialysis period. Clin Nephrol 2001; 55: 212–219 - PubMed
    1. Horl WH. Non-erythropoietin-based anaemia management in chronic kidney disease. Nephrol Dial Transplant 2002; 17 Suppl 11: 35–38 - PubMed